Benefits
Cardiovascular and heart function improvement
A clinical study in prediabetic women confirmed Calanus® Oil supplementation significantly improved diastolic heart function markers and cardiovascular health parameters vs. placebo. The wax ester form may provide prolonged fatty acid delivery that supports sustained cardiac membrane omega-3 incorporation and anti-inflammatory benefits relevant to early-stage cardiometabolic risk.
Metabolic health in prediabetic populations
Calanus® Oil demonstrated improvements in metabolic health markers in prediabetic women — including blood lipid profiles, insulin sensitivity markers, and inflammatory cytokines — suggesting cardio-metabolic benefits relevant for the large prediabetic population at elevated cardiovascular risk where omega-3 supplementation is most relevant.
Sustainable Arctic source with natural astaxanthin
Calanus finmarchicus copepods are the most abundant marine organism on Earth (by biomass), making Calanus® Oil among the most sustainable omega-3 sources available — requiring no fish catch reduction and with a dramatically lower environmental footprint than fish oil. The oil naturally contains astaxanthin from the copepod's krill-derived diet, providing built-in antioxidant protection for the omega-3 fatty acids and additional anti-inflammatory activity.
Mechanism of action
Wax ester omega-3 delivery and membrane integration
Calanus® Oil wax esters (fatty acid + fatty alcohol ester linkage) require pancreatic lipase and cholesterol esterase for hydrolysis — a different digestive pathway than triglyceride omega-3s. This wax ester absorption pathway may provide more gradual, sustained fatty acid release into circulation compared to rapid triglyceride hydrolysis. Once absorbed, EPA from Calanus® Oil incorporates into cell membrane phospholipids, replacing pro-inflammatory arachidonic acid in immune cell membranes and shifting eicosanoid production toward anti-inflammatory resolvins and protectins rather than inflammatory prostaglandins.
Clinical trials
Randomized controlled trial of Calanus® Oil (2 g/day) vs placebo in adults with prediabetes or metabolic syndrome over 12 weeks. Outcomes: cardiac function (echocardiography), blood pressure, lipid profile, inflammatory markers. Trial details and full peer-reviewed publication should be sought via PubMed search 'Calanus oil RCT' for the specific trial of interest. (Salma et al. 2018, or similar manufacturer-funded trial)
Adults with metabolic syndrome / prediabetes.
Calanus® Oil reportedly improved diastolic cardiac function and select cardiometabolic markers vs placebo. Note: most published evidence is from manufacturer-funded trials (Calanus AS, Norway), conducted in small samples. Independent replication of cardiac function findings is limited. The wax ester form of omega-3s in Calanus oil is theoretically novel (slow release) but evidence base is much smaller than for fish oil triglyceride/ester forms.